While the therapeutic strategies aimed at exclusively targeting RANTES/CCL5 or CCR5 were not successful in RA, these findings provide a rationale for testing HSPGs or signaling proteins as an adjunct therapeutic target to limit RASF participation in disease pathogenesis. Here, CCR5 is linked to rheumatoid arthritis.